Serine 162, an essential residue for the mitochondrial localization, stability and anti-apoptotic function of mcl-1. by Thomas, L et al.
Serine 162, an Essential Residue for the Mitochondrial
Localization, Stability and Anti-Apoptotic Function of
Mcl-1
Luke W. Thomas1., Connie Lam1., Richard E. Clark2, Michael R. H. White1¤, David G. Spiller1¤,
Robert J. Moots3, Steven W. Edwards1*
1 Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom, 2 Institute of Translational Medicine, University of Liverpool, Liverpool, United
Kingdom, 3 Institute of Aging and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
Abstract
Mcl-1 is an anti-apoptotic member of the Bcl-2 family that plays a key role in normal development, but also in pathologies
such as cancer. It has some unusual properties compared to other anti-apoptotic members of the Bcl-2 family, and its
expression and function are dynamically regulated by a variety of post-transcriptional and post-translational processes. Of
note, Mcl-1 protein has a very short half life, and its stability and function may be regulated by reversible phosphorylation.
There is also evidence to suggest that it may be localized to different subcellular compartments. The aim of this work was to
determine whether residues within the PEST region of Mcl-1 that may undergo reversible phosphorylation, also regulate its
subcellular distribution. We show that EGFP:Mcl-1 localizes mainly to the mitochondria of HeLa cells, with some additional
cytoplasmic and nuclear localization. The mutations, S64A, S64E, S121A, S159A, T163A and T163E did not significantly affect
the localization of Mcl-1. However, mutation of Ser162 to the phospho-null residue, Alanine resulted in an essentially
nuclear localization, with some cytoplasmic but no mitochondrial localization. This mutant Mcl-1 protein, S162A, showed
significantly decreased stability and it decreased the ability to protect against Bak-induced apoptosis. These data identify
a new molecular determinant of Mcl-1 function, localization and stability that may be important for understanding the role
of this protein in disease.
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Introduction
Mcl-1 is a crucial anti-apoptotic member of the Bcl-2 family
with unique properties that distinguish it from other family
members, such as Bcl-2 and Bcl-XL [1–3]. It was first discovered
as a gene induced early in the differentiation of ML-1 cells along
the monocyte/macrophage pathway [4] and since this discovery,
its importance and unique role in both normal physiology and
pathology is becoming recognized. For example, Mcl-1 plays a key
role in development, control of the cell cycle and resistance to
apoptosis [5,6] whereas defects in its expression underlie a number
of pathologies, such as impaired development/maintenance of B-
and T-lymphocytes [7] and enhanced apoptosis of differentiating
monocytic U-937 [8]. Over-expression of Mcl-1 underpins
malignancies that include multiple myeloma [9], hepatocellular
carcinomas [10], colon carcinomas [11] and chronic myeloid
leukaemia [12].
A key difference between Mcl-1 and other anti-apoptotic
proteins of the Bcl-2 family is its relatively large size. The protein
comprises 350 amino acids and residues 170–300 share structural/
functional homology to both Bcl-2 and Bcl-XL, which comprise
239 and 233 residues, respectively [13]. In spite of its larger size,
Mcl-1 possesses only 3 BH (Bcl-2 homology) domains, whereas
both Bcl-2 and Bcl-XL have 4. It also has a transmembrane
domain at its C-terminus, deletion of which disrupts its ability to
localize to sub-cellular membranes [14]. Despite this homology for
part of the molecule, Mcl-1 differs from its anti-apoptotic
counterparts in its binding affinities for pro-apoptotic proteins
[15]. Mcl-1 has an extensive N-terminal region, not present in
other family members, that confers many of its unique properties.
This region contains 2 large PEST domains, several potential
phosphorylation sites [16,17], 2 caspase cleavage sites [18], and it
is ubiquitinated by its own ubiquitin ligase (MULE) [19], which
targets Mcl-1 for proteasomal degradation. Its half-life is ,2–3 h
in cultured and primary cell lines, which is extended in response to
pro-survival agents, such as GM-CSF and bile acids [20,21], and
shortened in response to pro-apoptotic agents, such as sodium
salicylate [22]. Alternatively, caspases regulate Mcl-1 turnover
during accelerated apoptosis in response to high concentrations of
TNFa, by activating caspases 3, 8, 9 and 10 [23]. Mcl-1 is thus
a highly regulated anti-apoptotic protein, whose properties can be
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rapidly modulated via post-translational modifications, the major-
ity of which occur in its unique N-terminal PEST region.
A number of the residues that regulate Mcl-1 turnover and
stability have been mapped by mutagenesis, and these include key
Ser and Thr residues that undergo reversible phosphorylation [3]
and Lys residues that can become ubiquitinated [19]. A
mitochondrial targeting motif, EELD has been identified [24],
and in line with this observation, Mcl-1 localization is reported
mainly at the mitochondria [14,25–27] although some studies also
show nuclear localization [28,29]. This opens the possibility that
Mcl-1 localization may be functionally important, although
previous studies have not addressed this phenomenon.
The aims of the present study were to determine whether these
key phospho-residues in the PEST domains of Mcl-1 may regulate,
not only protein stability and turnover rates, but subcellular
localization. This was achieved by site-directed mutagenesis and
expression of GFP-linked wild type and mutant proteins, that were
visualized by live cell confocal microscopy. We make the novel
finding that mutagenesis of Ser162 to Ala, results in an essentially
nuclear localization of Mcl-1. Moreover, this nuclear-localized
protein is more unstable than the wild type protein and is less able
to protect against apoptosis.
Materials and Methods
Cell Culture
All cell lines were obtained from ATCC : HeLa human cervical
carcinoma cells were cultured in MEM (Gibco, UK) supplemented
with 10% FBS, 100 U/ml penicillin, 100 U/ml streptomycin and
1% NEAA; HEK-293 human embryonic kidney cells, were
cultured in DMEM (Gibco, UK) supplemented with 10% FBS,
100 U/ml penicillin, 100 U/ml streptomycin (Gibco, UK); MCF-
7 cells were cultured as above, but were additionally supplemented
with 5 mg/ml insulin and 1 mg/ml hydrocortisone.
Plasmids
For experiments measuring the subcellular localization of Mcl-
1, the following clones were generated. EGFP:Mcl-1 was
generated by standard PCR techniques to introduce the desired
restriction sites for ligation into pEGFP-C3 plasmid (Clontech,
USA). Bak cDNA was generated to introduce the desired
restriction sites for ligation into appropriately restriction digested
pENTR-2A entry vector for use in the Gateway cloning system
(Invitrogen, UK). Bak:EYFP was then generated by recombination
of Bak:ENTR-2A with the appropriate EYFP destination vector.
Mutant constructs were then generated by site-directed mutagen-
esis of Mcl-1:EGFP using the GeneTailor (Invitrogen, UK) whole
plasmid PCR method. This generated Mcl-1 clones containing
mutations in various phosphorylation sites that have previously
been reported to alter the stability or function of Mcl-1. All
mutants were verified by DNA sequencing.
For measurements of the turnover rate of wild type and mutant
Mcl-1, the following protocol was adopted. Mcl-1 cDNA was first
cloned into a pCMV-HA mammalian expression vector (Clontech
USA) to generate a hemagglutinin epitope (HA)-tagged construct.
HA-tagging of Mcl-1 allows distinction between exogenous
expression of Mcl-1 from the endogenous protein by western
blotting. HA:Mcl-1 was subsequently cloned into a pIRES2-EGFP
vector (Clontech USA) using primers designed to anneal to
hemagglutinin DNA. The generation of this HA-tagged pIRES-
EGFP plasmid, which contains the internal ribosome entry site
(IRES) of the encephalomyocarditis virus, permits the translation
of two proteins, HA-Mcl-1 that has been cloned into the multiple
cloning site and EGFP, from a single transcript.
Transfection and Microscopy
For microscopy experiments, cells were plated on 35 mm glass-
bottom microscopy dishes (Iwaki, Tokyo, Japan), at 756103 cells
per dish in 2 ml growth medium and incubated at 37uC and 5%
CO2. Cells were transfected with plasmids using Fugene 6
transfection reagent (Invitrogen) at a ratio of 2 ml Fugene 6 to
1 mg of DNA and cultured for 24 h prior to imaging. Confocal
fluorescence microscopy was carried out on transfected cells using
a Zeiss LSM510 Axiovert microscope with a 636 phase-contrast
oil-immersion objective (numerical aperture = 1.4). Excitation of
EGFP was performed using an Argon ion laser at 488 nm, and
emitted light was reflected through a 505–550 nm bandpass filter
from a 540 nm dichromatic mirror. EYFP fluorescence was
excited using an Argon ion laser at 514 nm, passed through
a 514 nm dichroic mirror and was collected through a 530 nm
long-pass filter. MitoTracker Red (Molecular Probes, Invitrogen,
UK) was added to cultures at 2 nM. Data capture and analysis was
carried out with LSM510 version 3 software (Zeiss, Germany).
Western Blotting
Protein stability of wild type or mutant Mcl-1 was assessed by
incubating cells in the presence of cycloheximide (10 mg/ml) to
inhibit de novo protein synthesis, and then measuring protein levels
by western blotting. At each time point, cells were rapidly lysed
using hot Laemmli buffer [5]. The HA antibody was utilized to
analyze the half life of exogenously-expressed Mcl-1 and the
mutants of interest, whilst the detection of EGFP was used to
control for the variations in transfection efficiency between
samples. Band intensities were measured using the AQM Advance
6 Kinetic Imaging program and data were expressed as
a percentage of 0 h treatment following standardization against
the EGFP control.
Statistical Analysis
Data sets were analyzed using the paired Student’s t test.
Results
Subcellular Localization of Wild Type and Mutant Mcl-1
Full length, wild type Mcl-1 localized primarily to the
mitochondria of HeLa cells, confirmed by its co-localization with
MitoTracker Red (Fig.1). All mitochondria co-stained for Mcl-1,
but EGFP:Mcl-1 could also be detected in the cytoplasm and
nucleus of the these cells, albeit at lower levels than found in
mitochondria. This pattern of EGFP:Mcl-1 localization was seen
in at least 25 separate transfection/imaging experiments and the
non-mitochondrial cytoplasmic and nuclear staining was consis-
tently observed, even when the transfected cells were expressing
low levels of EGFP:Mcl-1. Fluorescence Recovery After Photo-
bleaching (FRAP) experiments indicated that re-distribution of the
low level of nuclear EGFP:Mcl-1 occurred rapidly after nuclear
photobleaching (data not shown).
We then used site-directed mutagenesis to introduce mutations
to phospho-residues that have been reported to alter the properties
of Mcl-1, and then expressed these phospho-mutants in HeLa
cells. Residue Ser64 of Mcl-1 is reported to be highly phosphor-
ylated at the G2/M phase of the cell cycle by kinases such as
CDKs 1 and 2, C-Jun terminal kinase and to protect cells from
TRAIL-induced apoptosis [30]. The subcellular localization of
Ser64A (Fig. 2i, ii) and the phospho-mimetic, Ser64E (Fig.2iii, iv),
were very similar to those of the wild type protein, being localized
to mitochondria, but with some additional cytoplasmic and
nuclear localization. Serine 121 is reported to be phosphorylated
by JNK in response to oxidative stress [31,32], while Ser159 is
Serine 162 of Mcl-1 Controls Function
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phosphorylated by Glycogen Synthase Kinase (GSK) 3 [33–35].
Mutation of these residues to the phospho-null residue Ala, had no
effect on the subcellular localization of Mcl-1 (Fig. 2 v–viii).
Threonine 163 was the first phospho-residue of Mcl-1 to be shown
to be phosphorylated by 12-O-tetradecanoyl phorbol-13-acetate
(TPA) [17,31,34,36]). Mutation of Thr163 to Ala did not affect its
localization (Fig. 2ix) and similarly mutation of this residue to the
phospho-mimetic, T163E did not affect its subcellular distribution
(Fig. 2x).
Adjacent to Thr163, and contained within a consensus MAPK
site, is Serine 162. There are no previous reports of the properties
of this residue on Mcl-1 function. When we mutated this residue to
Ala (Ser162A), we noticed a remarkable shift in its subcellular
localization (Fig.3 top panel). This Mcl-1 mutant was now
localized primarily to the nucleus of HeLa cells, but was excluded
from the nucleolus. Whilst there was clear, but low level
cytoplasmic localization of this mutant protein, there was no
detectable localization to the mitochondria (Fig. 3iv, top panel).
This loss of mitochondrial localization and distribution to the
nucleus was also observed when this mutant form of Mcl-1 was
also transfected into other cells such as MCF-7 cells and Hek 293
cells (data not shown). The nuclear localization of this S162A
Figure 1. Subcellular localisation of wild type Mcl-1. Wild type EGFP-Mcl-1 was transfected and expressed in HeLa cells, co-stained with
MitoTrackerRed and live cell confocal imaging was performed as described in Experimental. i, shows confocal image of EGFP localization, ii,
MitoTrackerRed staining and iii, overlay of images i and ii. iv shows overlay images viewed at higher magnification. i–iii, bar marker represents 20 mm,
while in iv, bar marker represents 5 mm. Images are representative of at least 20 separate transfection experiments.
doi:10.1371/journal.pone.0045088.g001
Serine 162 of Mcl-1 Controls Function
PLOS ONE | www.plosone.org 3 September 2012 | Volume 7 | Issue 9 | e45088
mutant was confirmed in subcellular fractionation experiments.
These experiments showed that endogenous Mcl-1 localized
mostly to the non-nuclear fraction, whereas the S162A mutant
(GFP:tagged) localized almost exclusively the nucleus (Figure S1).
Furthermore, this subcellular fractionation experiment shows that
nuclear localization of the S162A mutant does not affect the
subcellular distribution of endogenous Mcl-1. When the phospho-
mimetic S162E was generated and transfected into HeLa cells, it
was found to localize similarly to the wild type protein, namely,
mainly in the mitochondria, but with some additional cytoplasmic
but minor nuclear staining (Fig. 3 bottom panel).
Stability of Wild Type and Mutant Mcl-1 Protein
A number of the previously identified phospho-residues of Mcl-
1 have been shown to affect its function, either by altering its
ability to protect against apoptosis, or else by altering its rate of
degradation [reviewed in 3]. The half life of the wild type of Mcl-1
protein has been measured in a number of cultured and primary
cells, and protein stability is dynamically-regulated, so that this half
life can be increased or decreased, depending upon the signals to
which the cell is exposed [20,22]. Various pathways of
proteasomal- or non-proteasomal degradation can occur, and
there is considerable evidence emerging to show that changes in
the phosphorylation status of some key residues on the protein can
affect its rate of turnover. Protein turnover rates can be measured
by blocking de novo biosynthesis with cycloheximide, and then
blotting for protein levels at various time points following the
inhibitor block. This method is particularly suitable for measure-
ment of the turnover rate of endogenously-expressed Mcl-1.
However, there are a number of potential technical problems
associated with measuring the rate of turnover of exogenously-
expressed proteins, because of varying levels of transfection of
different batches of cells. For example, when we transiently-
transfected HeLa cells with a plasmid allowing for the expression
of wild type or mutant Mcl-1, variability of transfection rates
between batches of cells, meant that no clear pattern of turnover
rate could be determined when blots were corrected for expression
of endogenously-expressed proteins such as actin or a-tubulin
(data not shown). To overcome this problem, we developed
a cloning strategy such that two exogenous proteins were
expressed from a single plasmid. Mcl-1 (or mutants thereof) was
first cloned into pCMV-HA, to generate a HA-tagged protein (to
distinguish exogenous Mcl-1 from endogenous protein). Sub-
sequently, HA:Mcl-1 cDNA was cloned into a pIRES-EGFP
plasmid to express a secondary protein (EGFP), quantification of
which served as a transfection control. Control experiments
showed that EGFP expressed in HeLa cells was relatively stable,
showing no loss of expression level following treatment of cells with
cycloheximide for periods of up to 8 h (data not shown).
Initial experiments were therefore conducted to determine the
protein half life of exogenously-expressed Mcl-1 in HeLa cells and
then to determine the effect of mutation of particular phospho-
residues on protein stability. Figure 4 shows data validating this
methodology with the half life of exogenously-expressed wild type
Mcl-1 being 1.36 h 60.2 h (determined by fitting the experimen-
tal data (n = 10) to first order decay kinetics). We then determined
the stability of some Mcl-1 mutant proteins, focusing first on those
residues that had been previously-reported to affect function or
stability. First, we measured the half-life of a double mutation of
T92A/T163A, as it has been reported that this double mutation
results in decreased stability of the protein [36]. Figure 4 A
confirms that Mcl-1 stability in this double mutant was decreased,
thereby validating the methodology. Threonine 163 is a well-
established phospho-residue of Mcl-1, that has been shown to be
Figure 2. Subcellular localisation of mutant Mcl-1. Experiments
were performed exactly as described in the legend to Figure 1. Images
shown are all overlay images of EGFP-Mcl-1 and MitoTrackerRed. The
following mutants are shown: i, ii, S64A; iii, iv, S64E; v, vi, S121A; vii, viii,
S159A; ix, T163A, x; T163E. Bar marker in i, iii, v, vii, ix and x represents
20 mm, while in ii, iv, vi and viii it represents 5 mm. Images shown are
representative of at least 10 separate transfection experiments with
each mutant.
doi:10.1371/journal.pone.0045088.g002
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phosphorylated by agents such as TPA and ERK [17,31,34].
While its importance in stabilizing Mcl-1 when phosphorylated by
TPA has been inferred, this has not been directly demonstrated
experimentally. The data in Figure 4B show that mutation of
Thr163 to either A or the phospho-mimetic, E resulted in only
small changes in Mcl-1 stability, but these did not reach statistical
significance. Serine 64 has been identified as a target of CDKs 1
and 2, C-Jun N-terminal kinase (JNK) and to be strongly
phosphorylated in the G2/M phase of the cell cycle [30]. The
data in Figure 4C show that whereas the mutant S64A had similar
stability to the wild type protein, the phospho-mimetic, S64E
demonstrated considerably enhanced stability.
The effects of mutation of Ser162 on the turnover rate of Mcl-1
were then determined. Mutation of this residue to the phospho-
mimetic, Ser162E, did not alter the rate of degradation, compared
to the rate of turnover of the wild type protein. However, the
turnover rate of the phospho-mutant S162A was significantly
enhanced compared to wild type protein (Fig. 4D). After 1 h
following cycloheximide addition, protein levels had decreased by
about 80%, indicating a half life of approx. 30 min. Hence, these
data suggest that this residue is responsible for regulating both the
subcellular location and the turnover rate of Mcl-1.
Role of Ser162 in Protection Against Apoptosis
We next designed experiments to determine whether the
nuclear localization and high turnover rate of mutant S162A
Mcl-1 also impaired its ability to protect against apoptosis. For
these experiments, we transfected HeLa cells with YFP-Bak so that
we could assess apoptosis and protein expression/localization by
confocal microscopy. When HeLa cells were transfected with YFP-
Bak alone, time-lapse experiments revealed that apoptosis was
initiated within minutes of the cells beginning to express this
apoptotic protein (data not shown). All cells expressing YFP-Bak
showed signs of apoptosis (Fig. 5A). When YFP-Bak was co-
expressed with wild type EGFP-Mcl-1, the cells showed normal
survival, suggesting that the pro-apoptotic effects of exogenous Bak
expression were counteracted by the co-expression of exogenous
wild type Mcl-1 (Fig. 5B). However, when YFP-Bak was co-
Figure 3. Subcellular localisation of S162 mutants. Experiments were performed exactly as described in the legend to Figure 1, except that
HeLa cells were transfected with mutants of residue S162 of Mcl-1. Top panel shows localisation of S162A EGFP:Mcl-1 as follows: i, EGFP:Mcl-1; ii,
MitotrackerRed; iii overlay and iv, enhanced magnification. Bar marker represents 20 mm in i-iii and 5 mm in iv. Bottom panel shows similar images but
for S162E Mcl-1.
doi:10.1371/journal.pone.0045088.g003
Figure 4. Stability of wild type and mutant Mcl-1 proteins. HeLa cells were transfected with a single plasmid allowing for the expression of
HA:Mcl-1 (wild type or mutant) and EGFP. Suspensions were treated with 30 mg/ml cycloheximide, and at time intervals after the addition of this
inhibitor of protein biosynthesis, samples were extracted in SDS-sample buffer prior to analysis of protein levels by western blotting. Expression of
exogenous Mcl-1 was determined by probing with anti-HA antibodies, while EGFP-expression was determined with an anti-GFP antibody. Signals
were quantified by densitometry and the level of expression of EGFP was used as a transfection control to normalize for Mcl-1 levels. In all panels ()
shows levels of wild type Mcl-1: in A the double T92A/T163A mutant is shown by (); in B, T163E shown by () and T163A by (); C, S64E by () and S64A by
(); D, S162E by () and S162A by (). Number of replicates ranges from n= 328 in each panel.
doi:10.1371/journal.pone.0045088.g004
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Figure 5. Protection from apoptosis wild type and S162AMcl-1. In A, HeLa cells were transfected to express YFP:Bak, either alone (i, ii) or with
wild type (iii-v) or S162A (vi-viii) Mcl-1. Images were taken from a time lapse series experiment for 24 h post transfection, as follows: (i) YFP:Bak
fluorescence plus merged bright field; (ii), YFP:Bak (showing apoptosis in cells expressing the pro-apoptotic protein; (iii), merged wild type EGFP:Mcl-1
Serine 162 of Mcl-1 Controls Function
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expressed with S162A EGFP-Mcl-1, then two observations were
made. Firstly, the mutant Mcl-1 protein appeared to be retained
within the nucleus and secondly, the cells were not protected
against apoptosis (Fig. 5C, D).
Discussion
In this report, we make the novel discovery that Ser162 is a key
regulator of the localization, turnover rate and function of Mcl-1,
and an important regulator of apoptosis. It is now established that
Mcl-1 has many unique properties compared to other anti-
apoptotic members of the Bcl-2 family, and that many of the
molecular motifs regulating these properties reside within the large
N-terminal domain of the protein that contains PEST domains.
This region contains proteolytic cleavage sites (for caspases and
other proteases), multiple phospho-residues (that control turnover
rate and function) and Lys residues (that become ubiquitinated
prior to proteasomal targeting and degradation). In addition to
these post-translation modifications affecting function, Mcl-1
expression is also regulated by alternative splicing (leading to the
expression of proteins with either pro-or anti-apoptotic properties),
changes in transcript stability and also translational control,
regulated by the binding of mir-29b and CUGBP2 to the 39-UTR
of the transcript [37,38]. All of these regulatory processes suggest
that Mcl-1 plays a unique and central role in the dynamic
regulation of cell death and survival in response to external signals.
Mcl-1 is proposed to interact with BH3 proteins such as Bak on
the mitochondrial membrane preventing such molecules from
dimerizing to form pro-apoptotic pores and subsequent cyto-
chrome c release. Our data (e.g. Fig.1), and that of other groups,
indicate a strong mitochondrial localization of wild type Mcl-1, in
accord with this anti-apoptotic function. However, Mcl-1 is also
localized to the cytoplasm and to a lesser extent, the nucleus of
many cells. We hypothesized that localization to these other non-
mitochondrial sites might be important for its function in cell
survival. A cytosolic localization of Mcl-1, for example, might be
required to sequester cytosolic Bax or similar proteins, while
a nuclear localization has been proposed to be required for
interactions with CDK-1 and PCNA, suggesting a role for Mcl-1
in cell cycle regulation or DNA repair [29,39]. While the
molecular motifs regulating the mitochondrial localization of
Mcl-1 are becoming defined [24], those regulating cytoplasmic or
nuclear localization remain unclear.
We show here that the subcellular distribution of the null
phospho-mutant, S162A is completely different to that of the wild
type protein, being localized primarily to the nucleus rather than
the mitochondria (Fig. 1, 3). However, a cytoplasmic localization
of S162A was still observed. These data suggest that changes in the
phosphorylation status of Mcl-1 on Ser162 may be the molecular
‘‘switch’’ that changes its localization from an essentially
mitochondrial location to a mainly nuclear distribution. We also
show that this change in sub-cellular distribution is associated with
changes in the function of this protein as the turnover rate and
ability to protect against Bak-induced apoptosis is altered in the
S162A mutant. These observations point to a key role for this
residue in regulating cell fate via reversible phosphorylation. We
propose that nuclear-localized Mcl-1, not phosphorylated on
Ser162, is unable to protect against pro-apoptotic events that
occur on the mitochondria. The corollary of this observation is
that phosphorylation of Ser162 is required for a mitochondrial
localization and hence functional of role of Mcl-1 in apoptosis
protection.
As part of our studies to determine the half-life of the S162A
mutant protein compared to that of the wild type protein, we
designed a new cloning/expression protocol that enabled us to
correct hybridization signals in western blots for variations in
transfection efficiency between different batches of cells. As our
mutagenesis approach necessitated the screening of many site-
directed mutants for Mcl-1, it was not feasible to generate stably
transfected cell lines for each of the mutants. Instead, our
screening strategy utilized transient transfections, but we encoun-
tered significant difficulties in ‘‘normalizing’’ western blot signals
between different batches of cells of varying transfection efficien-
cies. We therefore developed a system whereby two proteins, HA-
tagged Mcl-1 (or mutants thereof) and EGFP were expressed from
a single transcript using an IRES-containing bicistronic vector.
This enabled us to probe for levels of exogenous Mcl-1 (without
interference from endogenous Mcl-1) using an anti-HA antibody,
and to correct for transfection efficiency using an anti-EGFP
antibody.
Our first experiments showed that the rate of turnover of wild
type Mcl-1 is 1.65 h60.2 h, in line with many other reports that
this protein has a rapid rate of turnover in a variety of cell lines. It
was then necessary to determine if this assay had the sensitivity to
detect changes in degradation rates that resulted from mutagenesis
of specific residues. We therefore measured the turnover rates of
some Mcl-1 mutants that had been characterized in other
experimental systems. First, we showed that the double mutant
T92A/T163A had an increased rate of protein turnover,
confirming a previous report [36]. However, we did not measure
any change in turnover rate of either a T163A or T163E mutant,
compared to that of wild type Mcl-1. It has previously been
reported that TPA treatment of BL41-3 cells enhanced Mcl-1
stability and phosphorylates Thr163 [17] and TPA-induced Mcl-1
phosphorylation was decreased in a T163A mutant. It was
therefore inferred (but not experimentally tested) that phosphor-
ylation of Thr163 confers enhanced Mcl-1 stability. A number of
other reports have confirmed Thr163 phosphorylation and
determined its function, but usually in conjunction with a second
mutation, such as Ser121, Ser155 or Ser159 [31,34,36]. Apart
from the differences in cell lines used, our experiments also differ
in that we measured the effect of these mutations on the
endogenous, rather that TPA-regulated, turnover of wild type or
mutant Mcl-1.
Another finding from our study was the significantly-enhanced
stability of the S64E Mcl-1 mutant. Previous studies on this residue
have suggested its ability to undergo reversible phosphorylation,
and showed that a S64E mutant had enhanced stability in KMCH
cells (with endogenous Mcl-1 knocked down by shRNA treat-
ment). However, this change in stability was reported by the
authors to be non-significant [30]. In HeLa cells, we show that
after a 3 h incubation with the protein synthesis inhibitor,
cycloheximide, around 80% of the protein was still detected,
whereas by this time, only around 30% of the wild type protein
remained. Thus, we found that the most dramatic changes in the
stability of Mcl-1 protein were regulated by Ser162 (with S162A
being the most unstable form of the protein) and Ser64 (with S64E
being the most stable form). Differential phosphorylation on these
and YFP:Bak; (iv), YFP:Bak; (v) wild type EGFP:Mcl-1; (vi) merged bright field and fluorescence images of YFP:Bak and S162A EGFP:Mcl-1; (vii) YFP:Bak
and (viii) S162A EGFP:Mcl-1. B shows quantitative data of survival times of cells in culture following transfection with YFP:Bak, YFP:Bak plus wild type
EGFP:Mcl-1 and YFP:Bak plus S162A EGFP:Mcl-1. n = 54.
doi:10.1371/journal.pone.0045088.g005
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two residues by differential kinase/phosphatase activity, would
therefore lead to dramatic changes in protein stable stability. This
could have major effects on cell survival and apoptosis. It is now
necessary to identify the kinase/phosphatase systems responsible
for phosphorylation/dephosphorylation of Serine 162 and to
determine the patho-physiological stimuli that may control these
activities. Such information could be important for designing new
ways to induce apoptosis in cancer cells in which abnormal Mcl-1
expression underpins pathology.
Supporting Information
Figure S1 Non-transfected (control) and EGFP:Mcl-1
(S162A mutant) HeLa cells were fractionated into
cytoplasmic and nuclear fractions as using Thermo
Scientific NE-PER Nuclear and Cytoplasmic Extraction
Reagents, as per the manufacturer’s instructions (http://
www.piercenet.co). Following SDS-PAGE and transfer to PVDF
membranes as described in [23], cytoplasmic (C) and nuclear (N)
extracts of control (NT) and EGDP:Mcl-1 (S162A) transfected cells
were blotted with the following antibodies: Mcl-1 (which
recognizes the 40-kDa endogenous protein and the 60-kDa
exogenous (EGFP-tagged protein); EGFP (which recognizes only
exogenous Mcl-1); a-tubulin (a 50-kDa cytoplasmic protein); lamin
B (a 67-kDa nuclear protein).
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